Stay updated on TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page's navigation and metadata have been refreshed, adding revision 3.6.0, new help links (How to Read a Study Record, Common Questions, How to Join a Study), and labels such as Last verified; the Interventions header formatting was updated from 'Intervention / Treatment' to 'Intervention/Treatment'.
    Difference
    1%
    Check dated 2026-06-12T16:28:08.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page revision was bumped from v3.5.4 to v3.5.5, indicating a minor version update to the page rather than a substantive content change.
    Difference
    0.0%
    Check dated 2026-06-05T11:49:33.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This reflects an update to the page’s revision tag rather than substantive changes to study data or content.
    Difference
    0.0%
    Check dated 2026-05-15T03:11:48.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    Revision updated from v3.5.2 to v3.5.3, indicating a minor page maintenance or documentation update rather than changes to study details.
    Difference
    0.0%
    Check dated 2026-04-30T17:22:06.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Revision: v3.5.2 was added in the page footer, replacing Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T11:12:45.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Added publication: Grimm MO et al., Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024;10(6):755-764. Removed Erratum for the same article (JAMA Oncol. 2024 Nov 1;10(11):1598).
    Difference
    0.0%
    Check dated 2026-04-02T04:51:46.000Z thumbnail image

Stay in the know with updates to TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.